Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
2024年2月14日 - 8:04PM
Edgar (US Regulatory)
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SEC FILE NUMBER
000-55320 |
|
FORM 12b-25 |
CUSIP NUMBER
65343D 100 |
NOTIFICATION OF LATE FILING
(Check One): |
☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D |
|
☐ Form N-CEN ☐ Form N-CSR |
For Period Ended: December 31, 2023
|
☐ |
Transition Report on Form 10-K |
|
☐ |
Transition Report on Form 20-F |
|
☐ |
Transition Report on Form 11-K |
|
☐ |
Transition Report on Form 10-Q |
For the Transition Period Ended:__________________
Nothing in this form shall be construed to imply
that the Commission has verified any information contained herein.
If the notification relates to a portion
of the filing checked above, identify the Item(s) to which the notification relates:
PART I – REGISTRANT INFORMATION
Nexien BioPharma, Inc.
Full Name of Registrant
N/A
Former Name if Applicable
4340 E. Kentucky Ave. Suite 206
Address of Principal Executive Office (Street and Number)
Glendale, CO 80246
City, State and Zip Code
PART II – RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
☒ |
(a) |
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|
|
(c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III – NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F,
11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
The registrant’s current negotiations with lenders has delayed the
preparation and filing of the report.
PART IV – OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
Fay Matsukage |
|
(720) |
|
306-1001 |
(Name) |
|
(Area Code) |
|
(Telephone Number) |
(2) Have all other periodic reports required under
section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
☒ Yes
☐ No
(3) Is it anticipated that any significant change
in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
☐ Yes
☒ No
If so, attach an explanation of the anticipated change,
both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
Nexien BioPharma, Inc. |
|
|
(Name of Registrant as Specified in Charter) |
|
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: February 14, 2024 |
By: |
/s/ Evan Wasoff |
|
Name: |
Evan Wasoff |
|
Title: |
Chief Financial Officer |
Nexien BioPharma (PK) (USOTC:NXEN)
過去 株価チャート
から 11 2024 まで 12 2024
Nexien BioPharma (PK) (USOTC:NXEN)
過去 株価チャート
から 12 2023 まで 12 2024